Literature DB >> 25401168

Deregulation of the endogenous C/EBPβ LIP isoform predisposes to tumorigenesis.

Valérie Bégay1, Jeske J Smink, Christoph Loddenkemper, Karin Zimmermann, Cornelia Rudolph, Marina Scheller, Doris Steinemann, Ulf Leser, Brigitte Schlegelberger, Harald Stein, Achim Leutz.   

Abstract

UNLABELLED: Two long and one truncated isoforms (termed LAP*, LAP, and LIP, respectively) of the transcription factor CCAAT enhancer binding protein beta (C/EBPβ) are expressed from a single intronless Cebpb gene by alternative translation initiation. Isoform expression is sensitive to mammalian target of rapamycin (mTOR)-mediated activation of the translation initiation machinery and relayed through an upstream open reading frame (uORF) on the C/EBPβ mRNA. The truncated C/EBPβ LIP, initiated by high mTOR activity, has been implied in neoplasia, but it was never shown whether endogenous C/EBPβ LIP may function as an oncogene. In this study, we examined spontaneous tumor formation in C/EBPβ knockin mice that constitutively express only the C/EBPβ LIP isoform from its own locus. Our data show that deregulated C/EBPβ LIP predisposes to oncogenesis in many tissues. Gene expression profiling suggests that C/EBPβ LIP supports a pro-tumorigenic microenvironment, resistance to apoptosis, and alteration of cytokine/chemokine expression. The results imply that enhanced translation reinitiation of C/EBPβ LIP promotes tumorigenesis. Accordingly, pharmacological restriction of mTOR function might be a therapeutic option in tumorigenesis that involves enhanced expression of the truncated C/EBPβ LIP isoform. KEY MESSAGE: Elevated C/EBPβ LIP promotes cancer in mice. C/EBPβ LIP is upregulated in B-NHL. Deregulated C/EBPβ LIP alters apoptosis and cytokine/chemokine networks. Deregulated C/EBPβ LIP may support a pro-tumorigenic microenvironment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25401168     DOI: 10.1007/s00109-014-1215-5

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  42 in total

Review 1.  Transcriptional and translational control of C/EBPs: the case for "deep" genetics to understand physiological function.

Authors:  Claus Nerlov
Journal:  Bioessays       Date:  2010-08       Impact factor: 4.345

Review 2.  Faithfull modeling of PTEN loss driven diseases in the mouse.

Authors:  Caterina Nardella; Arkaitz Carracedo; Leonardo Salmena; Pier Paolo Pandolfi
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

3.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

4.  Overexpression of C/EBPbeta-LIP, a naturally occurring, dominant-negative transcription factor, in human breast cancer.

Authors:  C A Zahnow; P Younes; R Laucirica; J M Rosen
Journal:  J Natl Cancer Inst       Date:  1997-12-17       Impact factor: 13.506

5.  NPM-ALK-dependent expression of the transcription factor CCAAT/enhancer binding protein beta in ALK-positive anaplastic large cell lymphoma.

Authors:  Leticia Quintanilla-Martinez; Stefania Pittaluga; Cornelius Miething; Margit Klier; Martina Rudelius; Theresa Davies-Hill; Natasa Anastasov; Antonio Martinez; Angelica Vivero; Justus Duyster; Elaine S Jaffe; Falko Fend; Mark Raffeld
Journal:  Blood       Date:  2006-05-18       Impact factor: 22.113

Review 6.  CCAAT/enhancer-binding protein beta: its role in breast cancer and associations with receptor tyrosine kinases.

Authors:  Cynthia A Zahnow
Journal:  Expert Rev Mol Med       Date:  2009-04-08       Impact factor: 5.600

7.  The C/EBP beta isoform 34-kDa LAP is responsible for NF-IL-6-mediated gene induction in activated macrophages, but is not essential for intracellular bacteria killing.

Authors:  Satoshi Uematsu; Tsuneyasu Kaisho; Takashi Tanaka; Makoto Matsumoto; Megumi Yamakami; Hiroko Omori; Masahiro Yamamoto; Tamotsu Yoshimori; Shizuo Akira
Journal:  J Immunol       Date:  2007-10-15       Impact factor: 5.422

Review 8.  The C/EBP family of transcription factors: a paradigm for interaction between gene expression and proliferation control.

Authors:  Claus Nerlov
Journal:  Trends Cell Biol       Date:  2007-07-19       Impact factor: 20.808

9.  Differential control of the CCAAT/enhancer-binding protein beta (C/EBPbeta) products liver-enriched transcriptional activating protein (LAP) and liver-enriched transcriptional inhibitory protein (LIP) and the regulation of gene expression during the response to endoplasmic reticulum stress.

Authors:  Yi Li; Elena Bevilacqua; Calin-Bogdan Chiribau; Mithu Majumder; Chuanping Wang; Colleen M Croniger; Martin D Snider; Peter F Johnson; Maria Hatzoglou
Journal:  J Biol Chem       Date:  2008-06-11       Impact factor: 5.157

10.  Identification of C/EBPβ target genes in ALK+ anaplastic large cell lymphoma (ALCL) by gene expression profiling and chromatin immunoprecipitation.

Authors:  Irina Bonzheim; Martin Irmler; Margit Klier-Richter; Julia Steinhilber; Nataša Anastasov; Sabine Schäfer; Patrick Adam; Johannes Beckers; Mark Raffeld; Falko Fend; Leticia Quintanilla-Martinez
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

View more
  14 in total

Review 1.  C/EBPß Isoform Specific Gene Regulation: It's a Lot more Complicated than you Think!

Authors:  Aaron J Spike; Jeffrey M Rosen
Journal:  J Mammary Gland Biol Neoplasia       Date:  2020-02-20       Impact factor: 2.673

2.  C/EBPβ LIP induces a tumor menagerie making it an oncogene.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2015-01       Impact factor: 4.599

3.  EGFR and C/EBP-β oncogenic signaling is bidirectional in human glioma and varies with the C/EBP-β isoform.

Authors:  Ligia Selagea; Alok Mishra; Monika Anand; James Ross; Carol Tucker-Burden; Jun Kong; Daniel J Brat
Journal:  FASEB J       Date:  2016-08-29       Impact factor: 5.191

Review 4.  New frontiers in translational control of the cancer genome.

Authors:  Morgan L Truitt; Davide Ruggero
Journal:  Nat Rev Cancer       Date:  2016-04-26       Impact factor: 60.716

5.  EZH2 Supports Osteoclast Differentiation and Bone Resorption Via Epigenetic and Cytoplasmic Targets.

Authors:  Juraj Adamik; Sree H Pulugulla; Peng Zhang; Quanhong Sun; Konstantinos Lontos; David A Macar; Philip E Auron; Deborah L Galson
Journal:  J Bone Miner Res       Date:  2019-10-23       Impact factor: 6.741

6.  A screening strategy for the discovery of drugs that reduce C/EBPβ-LIP translation with potential calorie restriction mimetic properties.

Authors:  Mohamad A Zaini; Christine Müller; Tobias Ackermann; Jeanette Reinshagen; Gertrud Kortman; Ole Pless; Cornelis F Calkhoven
Journal:  Sci Rep       Date:  2017-02-15       Impact factor: 4.379

7.  The C/EBPβ LIP isoform rescues loss of C/EBPβ function in the mouse.

Authors:  Valérie Bégay; Christian Baumeier; Karin Zimmermann; Arnd Heuser; Achim Leutz
Journal:  Sci Rep       Date:  2018-05-30       Impact factor: 4.379

8.  Reduced expression of C/EBPβ-LIP extends health and lifespan in mice.

Authors:  Christine Müller; Laura M Zidek; Tobias Ackermann; Tristan de Jong; Peng Liu; Verena Kliche; Mohamad Amr Zaini; Gertrud Kortman; Liesbeth Harkema; Dineke S Verbeek; Jan P Tuckermann; Julia von Maltzahn; Alain de Bruin; Victor Guryev; Zhao-Qi Wang; Cornelis F Calkhoven
Journal:  Elife       Date:  2018-06-04       Impact factor: 8.140

9.  C/EBPβ-LIP induces cancer-type metabolic reprogramming by regulating the let-7/LIN28B circuit in mice.

Authors:  Götz Hartleben; Christine Müller; Tobias Ackermann; Guido Mastrobuoni; Marco Groth; Britt A Sterken; Mohamad A Zaini; Sameh A Youssef; Hidde R Zuidhof; Sara R Krauss; Gertrud Kortman; Gerald de Haan; Alain de Bruin; Zhao-Qi Wang; Matthias Platzer; Stefan Kempa; Cornelis F Calkhoven
Journal:  Commun Biol       Date:  2019-06-14

10.  The C/EBPδ protein is stabilized by estrogen receptor α activity, inhibits SNAI2 expression and associates with good prognosis in breast cancer.

Authors:  D Mendoza-Villanueva; K Balamurugan; H R Ali; S-R Kim; S Sharan; R C Johnson; A S Merchant; C Caldas; G Landberg; E Sterneck
Journal:  Oncogene       Date:  2016-05-16       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.